Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Colorcon
Medtronic
Harvard Business School
Boehringer Ingelheim

Last Updated: June 29, 2022

Investigational Drug Information for VTP-27999


✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug VTP-27999?

VTP-27999 is an investigational drug.

There have been 18 clinical trials for VTP-27999. The most recent clinical trial was a Phase 3 trial, which was initiated on January 21st 2019.

The most common disease conditions in clinical trials are Prostatic Neoplasms, Psoriasis, and Kidney Neoplasms. The leading clinical trial sponsors are Steba Biotech S.A., Vitae Pharmaceuticals, Inc., and Vitae Pharmaceuticals Inc., an Allergan affiliate.

There are fourteen US patents protecting this investigational drug and one hundred and thirty-five international patents.

Recent Clinical Trials for VTP-27999
TitleSponsorPhase
ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) StudyICON plcPhase 3
ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) StudyMedpace, Inc.Phase 3
ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) StudyPrimeVigilancePhase 3

See all VTP-27999 clinical trials

Clinical Trial Summary for VTP-27999

Top disease conditions for VTP-27999
Top clinical trial sponsors for VTP-27999

See all VTP-27999 clinical trials

US Patents for VTP-27999

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
VTP-27999 See Plans and Pricing sGC stimulators Ironwood Pharmaceuticals, Inc. (Cambridge, MA) See Plans and Pricing
VTP-27999 See Plans and Pricing sGC stimulators Ironwood Pharmaceuticals, Inc. (Cambridge, MA) See Plans and Pricing
VTP-27999 See Plans and Pricing sGC stimulators Cyclerion Therapeutics, Inc. (Cambridge, MA) See Plans and Pricing
VTP-27999 See Plans and Pricing sGC stimulators Cyclerion Therapeutics, Inc. (Cambridge, MA) See Plans and Pricing
VTP-27999 See Plans and Pricing sGC stimulators Cyclerion Therapeutics, Inc. (Cambridge, MA) See Plans and Pricing
VTP-27999 See Plans and Pricing Piperidine renin inhibitors Vitae Pharmaceuticals, Inc. (Fort Washington, PA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for VTP-27999

Drugname Country Document Number Estimated Expiration Related US Patent
VTP-27999 Australia AU2015317818 2034-09-17 See Plans and Pricing
VTP-27999 Brazil BR112017005248 2034-09-17 See Plans and Pricing
VTP-27999 Canada CA2961531 2034-09-17 See Plans and Pricing
VTP-27999 China CN107223125 2034-09-17 See Plans and Pricing
VTP-27999 Eurasian Patent Organization EA201790627 2034-09-17 See Plans and Pricing
VTP-27999 European Patent Office EP3194395 2034-09-17 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Colorcon
Medtronic
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.